MarketCap
Facebook
X
Telegram
Collegium Pharmaceutical Financial Ratios 2025-2011 | COLL
Brief overview of Collegium Pharmaceutical's valuation multiples
Ratios are assessed across five available annual reports in the 2020–2025 interval.
The valuation comparison uses P/E 22.19x (median 22.19x), EV/EBITDA 38.84x (median 46.3x), P/S 6.81x (median 2.25x). The combined ratio level is close to the company's five-year norm at a 0% deviation. No clear premium or discount is visible.
Earnings yield calculated as 1/P/E is about 4.5%, showing current profit per unit of share price.
Capital efficiency is characterized by ROE 20.9%, ROA 3.8%, ROCE 20.1%. Business quality is high on return ratios, supporting the ability to create value.
On PEG (0.29x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The cash conversion cycle increased 385.4 days to 537.3 days, weakening working-capital efficiency.
Conclusion
Collegium Pharmaceutical's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios Collegium Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
22.2 | 13.3 | 22.9 | -35.0 | 8.7 | 31.0 | -29.4 | -13.4 | -9.8 | -4.1 | -8.5 | - | - | - | - |
P/S |
6.8 | 5.0 | 1.9 | 1.9 | 2.3 | 2.7 | 2.3 | 1.9 | 25.8 | 228.3 | - | - | - | - | - |
EPS |
0.5 | 0.4 | 1.4 | -0.7 | 2.0 | 0.8 | -0.7 | -1.2 | -2.5 | -3.9 | -1.5 | -22.7 | -4.1 | - | - |
EV (Enterprise Value) |
2.52 B | 2.28 B | 1.81 B | 1.68 B | 926 M | 1.11 B | 718 M | 577 M | 646 M | 265 M | 148 M | 15.7 M | -4.1 M | - | - |
EBITDA per Share |
2.05 | 1.31 | 5.05 | 1.06 | 0.55 | 1.66 | -0.247 | 2.74 | -2.47 | -3.85 | -1.97 | - | - | - | - |
EV/EBITDA |
38.8 | 54.4 | 10.6 | 46.7 | 46.3 | 7.8 | -61.7 | 4.3 | -8.2 | -2.6 | -5.3 | - | - | - | - |
PEG |
0.29 | -0.15 | -0.24 | 0.16 | -0.04 | -0.15 | -0.69 | -0.26 | -0.27 | 0.03 | -0.18 | - | - | - | - |
P/B |
4.6 | 4.0 | 5.6 | 4.5 | 3.1 | 4.5 | 7.6 | 5.7 | 7.0 | 2.9 | 2.7 | - | - | - | - |
P/CF |
4.2 | 4.5 | 4.0 | 7.1 | 6.0 | 8.8 | 31.3 | 3.6 | -10.8 | -5.0 | -10.5 | - | - | - | - |
ROE % |
20.88 | 30.15 | 24.56 | -12.83 | 35.24 | 14.38 | -25.99 | -42.72 | -71.93 | -69.81 | -32.04 | - | - | - | - |
ROA % |
3.80 | 4.15 | 4.20 | -2.13 | 10.33 | 4.16 | -7.42 | -13.43 | -55.22 | -58.13 | -27.89 | - | - | - | - |
ROCE % |
20.14 | 16.65 | 85.43 | 17.10 | 8.69 | 30.23 | -22.72 | -20.26 | -72.49 | -68.96 | -30.14 | - | - | - | - |
Current Ratio |
1.2 | 1.2 | 1.2 | 1.2 | 1.4 | 1.4 | 1.3 | 1.3 | 4.2 | 6.2 | 11.5 | - | - | - | - |
DSO |
390.7 | 409.3 | 116.8 | 113.7 | 124.7 | 92.0 | 89.7 | 101.5 | 127.8 | 454.2 | - | - | - | - | - |
DIO |
181.1 | 148.1 | 59.8 | 45.8 | 47.7 | 35.4 | 18.2 | 17.2 | 255.0 | 2255.1 | - | - | - | - | - |
DPO |
34.6 | 27.5 | 9.2 | 5.5 | 20.5 | 22.8 | 11.8 | 26.8 | 799.5 | 15604.2 | - | - | - | - | - |
Operating Cycle |
571.8 | 557.4 | 176.6 | 159.5 | 172.4 | 127.4 | 107.9 | 118.7 | 382.8 | 2709.3 | - | - | - | - | - |
Cash Conversion Cycle |
537.3 | 529.9 | 167.3 | 154.0 | 151.9 | 104.6 | 96.1 | 91.9 | -416.7 | -12894.9 | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Collegium Pharmaceutical
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.46 | 0.45 | 1 | 0.38 | 0.08 | - | 0.29 | 0.6 | 0.86 | - | 0.61 | 0.38 | -0.51 | - | 0.01 | -0.15 | -0.39 | -0.73 | 0.23 | 2.06 | 0.45 | 0.2 | 0.33 | 0.23 | 0.01 | -0.07 | -0.18 | -0.14 | -0.29 | 0.27 | -0.5 | -0.4 | -0.57 | -0.54 | -0.45 | -0.72 | -0.79 | -1.02 | -1.13 | -1.05 | -0.68 | -0.46 | -0.46 | -0.45 | 0.34 | -4.5 | -7.85 | -5.33 | -5.03 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.17 | 0.98 | 2 | 1.14 | 0.72 | - | 1.11 | 1.49 | 1.56 | - | 2.41 | 2.11 | 0.74 | - | 1.7 | 1.43 | -0.28 | -0.51 | 0.44 | 0.94 | 0.62 | 0.92 | 0.59 | 0.49 | 0.15 | 0.04 | -0.17 | -0.14 | -0.29 | 0.33 | -0.32 | -0.2 | -0.39 | -0.54 | -0.45 | -0.72 | -0.78 | -1.02 | -1.11 | -1.04 | -0.67 | -0.46 | -0.44 | -0.38 | -3.58 | -3.48 | -6.77 | -4.31 | -4.05 | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
16.44 | 22.30 | 21.64 | 19.23 | 26.54 | 25.51 | 37.05 | 39.54 | 20.79 | 8.32 | 8.55 | -5.61 | -18.76 | -9.06 | -21.40 | -18.42 | 12.99 | 28.86 | 44.94 | 47.80 | 23.35 | 14.38 | 8.12 | -4.93 | -14.65 | -25.99 | -13.55 | -24.58 | -33.45 | -42.72 | -69.36 | -64.09 | -70.12 | -71.93 | -75.64 | -82.50 | -80.38 | -69.81 | -60.58 | -51.98 | -39.30 | -32.04 | -16.96 | 1.38 | 11.49 | 20.05 | 7.34 | 4.61 | 4.23 | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
2.89 | 3.74 | 3.43 | 3.33 | 4.33 | 4.18 | 5.26 | 3.25 | 1.39 | 1.39 | 1.43 | -1.37 | -6.06 | -4.63 | -3.54 | -3.58 | 6.62 | 10.10 | 14.80 | 15.46 | 6.51 | 4.16 | 2.36 | -1.39 | -4.18 | -7.42 | -3.58 | -7.25 | -10.20 | -13.43 | -29.39 | -33.51 | -44.60 | -55.22 | -59.40 | -65.93 | -65.49 | -58.13 | -50.86 | -44.12 | -33.77 | -27.89 | -86.30 | -205.52 | -281.62 | -352.00 | -128.80 | -80.88 | -74.17 | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
48.79 | 56.85 | 61.83 | 61.16 | 68.31 | 59.06 | 84.22 | 87.10 | 78.88 | 56.61 | 66.99 | 47.45 | 24.60 | 10.89 | -5.92 | -10.67 | -9.80 | 7.77 | 32.64 | 37.56 | 39.97 | 30.23 | 19.45 | 1.61 | -13.01 | -27.16 | -12.44 | -17.36 | -19.59 | -22.59 | -51.49 | -52.18 | -64.64 | -72.49 | -76.04 | -82.74 | -80.45 | -69.74 | -60.39 | -51.68 | -38.91 | -31.63 | -16.81 | 1.36 | 11.31 | 19.77 | 7.28 | 4.58 | 4.19 | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.3 | - | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | - | 1.2 | 1.4 | 1.5 | 1.6 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 | 4.3 | 4.3 | 4.3 | 4.3 | 6.0 | 6.0 | 6.0 | 6.0 | 7.7 | 7.7 | 7.7 | 7.7 | 0.3 | 0.3 | 0.3 | 0.3 | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
117.3 | 109.1 | 97.4 | 107.2 | 117.4 | - | 118.1 | 57.7 | 56.5 | - | 116.6 | 116.7 | 114.2 | - | 70.2 | 61.4 | 148.3 | 424.9 | 138.4 | 100.8 | 91.8 | 99.7 | 96.0 | 97.4 | 93.2 | 89.7 | 91.3 | 88.7 | 92.4 | 96.9 | 101.3 | 97.3 | 62.9 | 84.3 | 76.1 | 255.5 | 254.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
79.5 | 48.3 | 43.4 | 43.2 | 41.3 | - | 48.1 | 23.3 | 27.6 | - | 48.7 | 43.6 | 53.8 | - | 43.3 | 51.4 | 126.2 | 55.3 | 51.5 | 49.0 | 44.2 | 44.5 | 46.0 | 48.0 | 30.7 | 17.9 | 18.8 | 18.1 | 16.2 | 24.0 | 15.5 | 15.2 | 10.2 | 151.2 | 299.2 | 286.7 | 384.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
8.2 | 8.7 | 10.6 | 16.5 | 12.4 | - | 4.0 | 2.0 | 7.4 | - | 4.9 | 4.0 | 4.4 | - | 5.1 | 2.5 | 10.4 | 18.9 | 21.3 | 22.6 | 26.5 | 28.6 | 29.5 | 30.8 | 19.8 | 11.6 | 12.2 | 11.7 | 17.1 | 37.3 | 24.1 | 23.7 | 18.9 | 474.1 | 937.9 | 898.9 | 1818.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 140.8 | 150.4 | 158.6 | - | 166.2 | - | - | - | 165.2 | 160.2 | 167.9 | - | 113.5 | 112.8 | 274.5 | 480.2 | 189.9 | 149.8 | 136.0 | 144.2 | 142.0 | 145.4 | 123.9 | 107.6 | 110.1 | 106.8 | 108.6 | 120.9 | 116.8 | 112.6 | 73.1 | 235.5 | 375.3 | 542.2 | 638.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 130.2 | 133.9 | 146.3 | - | 162.1 | - | - | - | 160.3 | 156.2 | 163.6 | - | 108.3 | 110.3 | 264.1 | 461.2 | 168.6 | 127.2 | 109.5 | 115.7 | 112.5 | 114.6 | 104.1 | 96.0 | 97.9 | 95.1 | 91.5 | 83.6 | 92.8 | 88.9 | 54.2 | -238.6 | -562.6 | -356.6 | -1179.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Collegium Pharmaceutical, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
